|
The latest Mainline newsletters for the General Public are listed here. |
For healthcare professionals we have a Mainline newsletter in a Professional version here. |
Mainline |
||
| Volume 2 | December 2, 2005 | Number 12 |
An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service |
||
Medication News & Update
Second Generation Antidepressant Agents Compared:
A recent article appearing in the Annals of Internal Medicine indicates that there appears to be little difference in efficacy with respect to treating major depressive disorders in this group of agents. The agents compared were six SSRI agnets, buproprion, duloxetine, mirtazapine and venlafaxine.
The article indicated that approximately 96% of the studies in head – to – head trials done by the researchers at the University of North Carolina Chapel Hill (46 randomized controlled trials and 21 observational studies) to compare efficacy and tolerability had at least 1 author affiliated with a pharmaceutical company.
The end result was only minimal differences were noted in efficacy. Based on this information the clinician should make the selection of the agent based on side effect profile, approved indications, cost considerations and formulary restrictions.
For more information see the article in Annals of Intenal Medicine 2005; 143:415-426.
|
[ Home ]
[ About Us ]
[ Assessment Tools ]
[ Sample Consult ] |
